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Abstract
Several studies have shown that cancers actively regulate alternative splicing. Altered splicing mechanisms in cancer lead to
cancer-specific transcripts different from the pool of transcripts occurring only in healthy tissue. At the same time, altered
presentation of HLA class I epitopes is frequently observed in various types of cancer. Down-regulation of genes related to
HLA class I antigen processing has been observed in several cancer types, leading to fewer HLA class I antigens on the cell
surface. Here, we use a peptidome wide analysis of predicted alternative splice forms, based on a publicly available
database, to show that peptides over-represented in cancer splice variants comprise significantly fewer predicted HLA class I
epitopes compared to peptides from normal transcripts. Peptides over-represented in cancer transcripts are in the case of
the three most common HLA class I supertype representatives consistently found to contain fewer predicted epitopes
compared to normal tissue. We observed a significant difference in amino acid composition between protein sequences
associated with normal versus cancer tissue, as transcripts found in cancer are enriched with hydrophilic amino acids. This
variation contributes to the observed significant lower likelihood of cancer-specific peptides to be predicted epitopes
compared to peptides found in normal tissue.
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Introduction
Cancer-specific splice variants are of significant interest as they
may be involved in pathogenesis and may further potentially be
used as biomarkers and generate novel targets for cancer [1,2].
The human immune system is capable of responding to some of
these cancer specific antigens, as first shown by a melanoma-
specific antigen, MAGE-1, able to stimulate human T cells [3,4].
More generally, individuals with high or medium cytotoxic activity
of peripheral-blood lymphocytes are further associated with a
significantly lower risk of cancer, suggesting a role for natural
immunological host defense mechanisms in cancer [5].
Alternative splicing can change the structure of mRNA by
inclusion or skipping of exons, and this may alter the function,
stability or binding properties of encoded proteins and thereby
contribute to human diseases such as cancer [6]. In a study
investigating alternative splicing events in ovarian and breast tissues
affected by tumors it was found that about half of all splicing events
in these tissues are altered in tumors, many of them due to exon
skipping [7]. Similar trends have been observed in other types of
cancers, e.g., in colon cancer and testicular tumor [8,9], as well as in
gastric cancer, where genes showing differential expression between
cancer cell lines and corresponding normal tissues were found [10].
In addition to cancer being involved in dysregulating pathways, thus
contributing to changes in alternative splicing and gene expression
controlled by these proteins [11], human leukocyte antigen (HLA)
class I antigen processing components andHLA expression have also
been shown to be downregulated in connection with cancer [12,13].
A study investigating alterations of HLA class I expression in 12
ovarian cancer patients reported low levels of HLA class I antigens in
tumor cells from all patients. One patient-derived tumor cell line
showed a complete haplotype loss, including the HLA-A2 locus [14].
These observations are interpreted as mechanisms adopted by
tumors to escape immune surveillance and to avoid tumor cell
recognition and destruction [15,16]. It has been suggested that
elimination of growing tumors by the immune system may lead to
selection of tumor variants that are efficient in avoiding immune
system recognition [17]. There thus seems to be accumulative
evidence for cancer being coupled to alternative splicing as well as
to an efficacy in evasion from the immune system by downreg-
ulation and altering HLA expression. Most of the studies relating
cancer-specific alternative splicing to altered immune system
surveillance are, however, of limited size and in most cases
anecdotal. Here, we wanted to investigate, in a large-scale study, if
the alternative cancer exome already at the step of mRNA splicing
contains a bias compared to normal transcripts in the set of
possible HLA class I epitopes.
Results
Transcripts over-represented in cancer contain fewer
predicted epitopes restricted by the three most common
HLA class I supertypes
The aim of this study was to investigate, using a large-scale data
set, if peptidomes specific for cancer versus normal tissue have
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different properties related to altered degree of immune system
surveillance. To do this, we constructed two sets of peptides, one
over-represented by cancer tissue and one over-represented by
normal tissue. Globally permutated versions of these sets were
produced as described in Material and Methods. The global
permutation destroys structural characteristics within the HLA-
binding 9-mers, only maintaining global compositional properties.
For comparison, we constructed locally permutated normal and
cancer sets by permutating each peptide separately, thus
preserving the local amino acid composition of each peptide. To
investigate immune-related properties, potential epitopes covering
all 12 HLA class I supertypes were predicted using NetMHCpan.
For each supertype, we calculated the percentages of predicted
epitopes for the six peptide data sets: normal, normal globally and
normal locally permutated, cancer and cancer globally and cancer
locally permutated.
It is well known that some HLA class I supertype representatives
are more common than others. It is therefore expected that for the
less frequent HLA alleles, the results are more likely to include
noise. The source of our data set, the ASTD database, is to a large
extent originating from EST data without HLA specific informa-
tion. EST data is mostly based on Caucasian Europeans [18];
therefore we can safely assume that the more common HLA types
in the European population are also more common in our dataset.
The HLA allele frequencies were obtained from the dbMHC
database [19]. Approximate numbers of expected phenotype per
supertype in the European population are given in Table 1.
The three most common supertype representatives in the
European population are HLA-A*02:01, HLA-A*01:01 and HLA-
A*03:01. For these three supertype representatives, the transcripts
associated with normal tissue have a significantly higher percent-
age of predicted epitopes than transcripts over-represented in
cancer. Figure 1 shows the observed numbers, in percentages of
predicted epitopes per 9-mers, for the different data sets for these
three most common supertype representatives. All observed
differences between normal and cancer tissues shown in Figure 1
are significant (p,0.006, 2-sample test for equality of proportions).
For most HLA class I supertypes, cancer transcripts
contain fewer predicted epitopes
Further, the percentage of predicted epitopes for permutated
and not-permutated sequences for all 12 supertype representatives
is shown in Table 2. Here, we observed a similar tendency as
compared to our observation for the three most common
supertypes in the European population. For non-permutated
sequences, seven out of the twelve supertype representatives (HLA-
A*01:01, HLA-A*02:01, HLA-A*03:01, HLA-A*24:02, HLA-
A*26:01, HLA-B*15:01 and HLA-B*58:01) had a significant
lower fraction of predicted epitopes in sequences assigned to
cancer pathology. A statistical significant difference, where cancer-
associated peptides contained more predicted epitopes was, on the
other hand, only observed for one supertype representative,
namely HLA-B*27:05.
When analyzing permutated sequences, similar results were
observed. Only one supertype representative (HLA-B*40:01,
locally permutated) had significantly more predicted epitopes in
the permutated cancer sequences than in the permutated normal
sequences. On the other hand, permutated, normal sequences had
consistently for both the local and global permutated sets more
predicted epitopes for seven supertype representatives (HLA-
A*01:01, HLA-A*02:01, HLA-A*03:01, HLA-A*24:02, HLA-
A*26:01, HLA-B*15:01, HLA-B*58:01). For these seven supertype
representatives, the difference between normal and cancer data
sets is significant in the permutated as well the non-permutated
data sets. The observation that cancer transcripts contain fewer
predicted epitopes for most HLA class I supertype representatives,
is stable, when different thresholds for the prediction of potential
epitopes are applied (data not shown).
HLA motif and amino acid composition biases
The relative difference in predicted epitope density between
normal and cancer is, for our previously defined most common
HLA alleles, relatively stable. Also, the difference in epitope
density is largest when comparing non-permutated to globally
permutated peptide sets. For HLA-A*02:01, a noticeable decrease
of predicted epitopes is observed when comparing normal and
cancer non-permutated peptides to normal and cancer permutated
peptides. As seen from Table 2 and Figure 1, the difference in
percentage of epitopes is the largest when comparing the non-
permutated sequences to the globally permutated sequences
(normal: 0.83 vs 0.73, cancer: 0.77 vs 0.69). For HLA-A*01:01,
the percentage of epitopes in non-permutated versus permutated
sequences appears to be relative stable (normal: 0.82 vs 0.80,
cancer: 0.77 vs 0.76), whereas permutated HLA-A*03:01 sequenc-
es have more predicted epitopes than the corresponding non-
permutated sequences (normal: 0.94 vs 1.01, cancer: 0.91 vs 0.96).
For these three supertype representatives, the percentage of
predicted epitopes in locally permutated peptides always falls
between the respective percentages for non-permutated and
globally permutated sequences. Locally permutated peptides
preserve only local amino acid composition, and globally
permutated peptides have their local structural properties
destroyed and preserve only global amino acid composition.
These observations indicate that both global and local structural
amino acid properties are factors that define the observed
differences in the epitope densities between the normal and
cancer peptidome.
An analysis of relative amino acid composition was performed
for all over-represented 9-mers associated with normal and cancer.
We found that hydrophilic residues are more common in
polypeptides from cancer transcripts than from the normal
polypeptides. The relations of N/C ratios compared to the
Table 1. Phenotype frequencies.
Allele Frequency
HLA-A*02:01 0.47
HLA-A*01:01 0.30
HLA-A*03:01 0.26
HLA-B*07:02 0.24
HLA-B*08:01 0.22
HLA-A*24:02 0.13
HLA-B*40:01 0.10
HLA-B*15:01 0.07
HLA-B*27:05 0.06
HLA-A*26:01 0.05
HLA-B*39:01 0.02
HLA-B*58:01 0.02
HLA frequencies in the European population. Data obtained from the dbMHC
database [19].
doi:10.1371/journal.pone.0038670.t001
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hydrophilicity scale of amino acids by Hopp-Woods, the
hydrophobicity scale by Wimley-White as well as the mean
ranking of amino acids according to the frequency of their
occurrence for 38 published hydrophobicity scales are shown in
Figure 2. In Figure 2, residues are more common in cancer if N/C
is smaller than 1. Hydrophilic residues are marked black.
The Hopp-Woods and Wimley-White scales correlate strongly
with the N/C ratios with a Spearman rank correlation coefficient
of 20.72 and 0.78, respectively. The mean ranking amino acid
scale is correlated with a correlation coefficient of 20.65. All three
correlation coefficients are significant (P-value ,0.003, exact
permutation test). No correlation was found for other amino acid
properties like mass, surface area or volume (data not shown).
It is striking to observe that all strong hydrophilic amino acids
(KPRQ, Hopp-Woods scale) are enriched in sequences associated
with cancer. A similar observation is made for Wimley-White
scale: We identified seven amino acids significantly more common
in cancer (APERKDQ). Six of these (all except A) are within the
seven most hydrophilic amino acids based on the Wimley-White
scale. A reversed trend is found for hydrophobic amino acids. The
Figure 1. Percentage of epitopes per 9-mer comparison. Data is shown for the three most common HLA-I alleles in the European population.
Each bar shows the percentage of predicted epitopes per 9-mer in the respective set. Each set consists of peptides that are either over-represented in
normal or cancer tissue. Globally permutated or locally permutated version of the peptide sets were constructed as described in Materials and
Methods. All observed differences between cancer and normal tissues are significant (p,0.006, 2-sample test for equality of proportions).
doi:10.1371/journal.pone.0038670.g001
Table 2. Epitopes per set for all supertype representatives.
% epitopes % epitopes globally permutated % epitopes locally permutated
Allele N C N/C P-val N C N/C P-val N C N/C P-val
HLA-A*01:01 0.82 0.77 1.06 0.000 0.80 0.76 1.06 0.000 0.81 0.76 1.07 0.000
HLA-A*02:01 0.83 0.77 1.08 0.000 0.73 0.69 1.05 0.000 0.79 0.71 1.10 0.000
HLA-A*03:01 0.94 0.91 1.04 0.002 1.01 0.96 1.05 0.000 0.96 0.92 1.04 0.005
HLA-A*24:02 0.89 0.79 1.13 0.000 0.77 0.70 1.11 0.000 0.89 0.77 1.15 0.000
HLA-A*26:01 0.76 0.71 1.07 0.000 0.70 0.66 1.06 0.000 0.71 0.68 1.05 0.001
HLA-B*07:02 1.29 1.30 1.00 1.000 1.27 1.29 0.99 1.000 1.25 1.28 0.97 0.054
HLA-B*08:01 1.02 1.03 0.99 1.000 1.00 0.99 1.01 1.000 0.97 0.97 1.00 1.000
HLA-B*15:01 0.86 0.79 1.09 0.000 0.83 0.77 1.08 0.000 0.85 0.79 1.07 0.000
HLA-B*27:05 0.99 1.02 0.97 0.021 0.99 1.00 0.98 1.000 1.04 1.04 0.99 1.000
HLA-B*39:01 0.97 0.96 1.02 0.985 1.05 1.02 1.02 0.221 1.01 1.00 1.01 1.000
HLA-B*40:01 0.87 0.89 0.98 1.000 1.03 1.06 0.98 0.325 0.95 0.99 0.96 0.002
HLA-B*58:01 1.01 0.91 1.11 0.000 0.99 0.89 1.10 0.000 0.98 0.91 1.08 0.000
Percentage of predicted epitopes is given for data extracted from the ASTD database as well as for permutated sequences. N/C is the ratio between the normal and
cancer percentages. P-values are calculated by two-tailed t-test and adjusted for multiple testing by Bonferroni correction.
doi:10.1371/journal.pone.0038670.t002
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top significant amino acids classified by both Hopp-Woods and
Wimley-Scott as hydrophobic (WFICM) are all more common in
sequences associated with transcripts from normal tissue.
Based on these findings, one could suggest an explanation for
the difference in epitope density between the normal and cancer
peptidome. The binding motifs for the 3 most frequent supertype
representatives are shown in Figure 3. Out of the four most
preferred amino acids at the HLA-A*02:01 anchor positions, three
amino acids (VMI) are enriched in normal transcripts, whereas
only one (L) is as common in normal as in cancer. This leads to the
conclusion that at least part of the observed differences in
percentage of predicted epitopes in normal versus cancer
transcripts are due to amino acid composition. The same tendency
is found for HLA-A*01:01. The two most frequent amino acids in
the motif (YT) are also more often found in normal tissue, whereas
S is neutral and the next common amino acid, D, is more common
in cancer. The most frequent amino acid for HLA-A*03:01(K) is
slightly more common in cancer, whereas the second-next
frequent (Y) is, due to a stronger preference to fit peptides from
normal tissues, shifting the bias towards amino acids more
common in splice variants associated with normal tissue. For all
three motifs, we further calculated average weighted biases, based
on N/C ratios and amino acid frequencies (see materials and
methods). The weighted biases were calculated for both the
respective 5 most frequent amino acids per motif as well as all 20
amino acids. For all three motifs we observed an overall preference
for amino acids found in our normal tissue set.
Discussion
Alternative splicing of mRNA transcripts is an important
mechanism for generating genomic complexity and has been
shown to differ between cancer and the corresponding normal
tissues [1,8,9]. In addition, cancers in some cases downregulate
HLA class I antigen-processing components and HLA class I
expression to avoid detection by the immune system. These
observations led us to investigate whether transcripts found in
cancer tissue share characteristics that would reduce immune
system recognition. Here, we have carried out a large-scale
analysis aiming at identifying immune system related imprints that
can differentiate cancer from normal transcripts. Based on ASTD
database, a database providing predicted splice forms, we
identified two peptide data sets; one associated with transcripts
over-represented in cancer and one associated with transcripts
over-represented in normal tissue. Using state-of-the-art immu-
noinformatics prediction tools, we next analyzed the two data sets
for differences in terms of likelihood of being presented on
prevalent HLA class I molecules, and hence potential for
activating the immune system.
We found that peptides, which due to alternative splicing are
expressed in cancer tissue, contain fewer predicted epitopes
restricted by the three most common HLA class I alleles than
peptides expressed in normal tissue. Using globally permuted data
sets we consistently, for the three most common HLA class I
alleles, found that the observed loss in epitope density in the cancer
peptidome is maintained also for the permuted data sets. This
strongly indicates that differences in amino acid composition
between peptides from alternatively spliced normal and cancer
transcripts are the driving force of the reduced predicted epitope
density.
The reason for the observed change in frequency of specific
amino acids in proteins associated with cancer as compared to
normal tissue is unknown, but the phenomenon has previously
been observed in studies aiming at identifying biomarkers for early
stage detection of cancer: In a recent study, the levels of alanine,
isoleucine, leucine and valanine were found to be increased in the
pancreases of rats with pancreatic cancer as compared to samples
from rats with chronic pancreatitis and healthy rats [20]. In
another study, the levels of N-methylalanine and lysine were found
to be significantly increased in the plasma from pancreatic cancer
patients, while the level of glutamine and phenylalanine was found
to be decreased [21]. These studies identified differences in amino
acid composition in a single cancer type based on blood plasma
and tissue samples. We, in contrast, analyze over-represented
cancer peptides in general. As to be expected, the findings
regarding amino acid concentration reported in this study are not
concurrent with those of the single cancer type studies.
A possible explanation as to why we observed fewer predicted
epitopes in peptides, which due to alternative splicing are
expressed in cancer, could be that the host’s immune system
restricts the cancer exome. In that case, pressure from the immune
system disfavors cancer cells that present new epitopes at the cell
surface. An alternative explanation – which does not exclude the
previous explanation – takes as starting point the observed change
Figure 2. Hydrophilic amino acids are enriched in cancer. N/C
ratios in relation to Hopp-Woods hydrophilicity scale (A), Wimley-White
hydrophobicity scale (B) and to the mean ranking of amino acids based
on 38 hydrophobicity scales (C). N/C ratio is the ratio of observed
frequencies of the respective amino acids in polypeptides of over-
represented transcripts from normal and cancer tissues. If the N/C value
.1, the amino acid is more common in normal tissue; If the N/C value
,1, the amino acid is more common in cancer. Green bars refer to more
hydrophobic amino acids, whereas black bars refer to more hydrophilic
amino acids. All N/C ratios larger or smaller than 1 are significant
(p,0.001, calculated using the Wilson score [45] and Bonferroni
corrected).
doi:10.1371/journal.pone.0038670.g002
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in amino acid frequency, especially the increase in hydrophilic
amino acids in cancer proteins.
It has previously been shown that missense mutations in the
BRCA domain of high-risk breast and ovarian cancer patients
frequently target strongly hydrophobic amino acids [22]. Further,
it has been suggested that the stabilization of a protein structure is
to a large part due to the hydrophobic effect [23]. Accordingly, the
increase in hydrophilic amino acids has a destabilizing effect on
protein structure, which is in concordance with the protein loss-of-
function that is correlated with cancer progression. This is
exemplified by a study concerning inherited missense mutations
of the tumor suppressor gene, BRCA-1, which may predispose to
breast or ovarian cancer [24]. In this study, it was found that the
mutations predominately target conserved hydrophobic amino
acids that are responsible for folding and stability. Since, in
particular, the most common HLA class I allele, A*02:01, prefers
hydrophobic amino acids at the anchor positions, an increase in
hydrophilic amino acids will inevitably lead to fewer predicted
epitopes. The reduction in epitope density in peptides associated
with cancer might therefore be an intrinsic property of proteins
that are destabilized by a decrease of hydrophobic amino acids as
part of the progression to cancer. We are, however, not aware of
studies that show a general increase of hydrophobic amino acids
throughout different forms of cancer.
A bias of fewer potential epitopes due to cancer was previously
shown by Wiedenfeld et al [25]. Peptides caused by missense
mutations of p53 were shown to have a decreased fit to the HLA-
A*02:01 motif. All predicted variants of the peptides were either
from patients with other alleles or the allele was lost during
tumorigenesis. The decreased fit to the HLA motif due to
mutations is in coherence with our study investigating differences
in epitope density due to alternative splicing. To our knowledge,
this is the first study indicating that alternatively spliced cancer
transcripts tend to express fewer potential epitopes than alterna-
tively spliced transcripts found in normal tissue. The identified
difference in amino acid composition towards hydrophilic amino
acids in the alternative spliced cancer exome is a possible
explanation for the bias in potential HLA class I epitopes. The
preference for hydrophilic amino acids at the step of alternative
mRNA splicing could support the development of cancer by
providing it with the possibility of evading the host’s immune
system. In this case by leading to fewer potential HLA class I
epitopes presented at the cell surface.
Materials and Methods
Data extraction from the ASTD database
The Alternative Splicing and Transcript Diversity database
(ASTD) provides access to a collection of alternative splice events
and transcripts of genes from human, mouse and rat [26]. The aim
of the database is to analyze the mechanisms of alternative splicing
on a genome-wide scale. It integrates a computational pipeline for
detection and characterization of isoform splice patterns as well as
alternative introns and exons. The database contains predicted
transcripts, generated by mapping expressed sequence tags (ESTs)
to genome sequences. Our study is based on ASTD version v1.1
build 9 (accessible at ftp://ftp.ebi.ac.uk/pub/databases/astd/).
The database covers 14,194 human genes and lists 50,581 unique
transcripts not covered by Ensembl genes. Based on related
evidences from cDNA libraries, many of these transcripts are
tagged with pathology information. The pathology information is
given as eVOC ontologies, which is a controlled vocabulary for
unifying gene expression data [27]. As an alternative to the ASTD
database, we would have liked to use RNA sequence data, but
could not identify any usable database, providing genome-wide
coverage of potential transcripts, together with pathology
information.
Two data sets were generated based on annotated pathology
information. All transcripts tagged with the information of being
expressed in normal tissue were assigned to subset N. This subset
consisted of 30,739 transcripts derived from 11,980 genes. A
second subset, C, with transcripts related to cancer, consisted of
27,967 transcripts derived from 10,730 genes.
The cancer subset consists of all transcripts tagged with eVOC
terms related to cancer; that is being a subgroup of tumor in the
eVOC ontology hierarchy (Table 3). Several eVOC terms can be
associated to the same transcript.
For our analysis, we were interested in transcripts uniquely
associated to normal tissue or to one or more of the cancer eVOC
terms. Two new subsets consisting of transcripts only associated to
either normal or cancer eVOC terms were created. Out of 30,739
transcripts associated to normal, 16,566 were uniquely associated
Figure 3. Human HLA motifs. The three most common HLA types in the European population. The height of a column of letters is equal to the
information content at that position, whereas the height of each letter within a column is proportional to the frequency of the corresponding amino
acid at that position [44].
doi:10.1371/journal.pone.0038670.g003
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with normal tissue, due to ASTD database, and not with cancer
(unique N set). The subset of transcripts uniquely associated with
cancer (unique C set) consists of 13,794 transcripts (see Table 4).
Transcripts covered by each data set are unique for either normal
tissue or cancer as defined by the ASTD database. The ASTD
database does not provide pathology information for all transcripts
nor lists all potential tissue types or pathologies. Accordingly, we
refer to our sets of transcripts uniquely associated to either normal
or cancer as over-represented in either normal or cancer tissue.
Translation to proteins
All transcripts assigned to either normal or cancer pathology
were translated to their respective protein sequence using Virtual
Ribosome [28]. The longest ORF among all three reading frames
was chosen as the translated protein sequence. The protein
sequence and corresponding transcript were discarded if no ORF
was found or if the resulting protein sequence was shorter than 9
amino acids. The threshold of 9 amino acids was chosen as we
subsequently apply the epitope prediction on 9-meric peptides,
although we are aware that proteins this small might not be
functional. Applying this filter resulted in a normal set of 16,490
transcripts and a cancer set of 13,721 transcripts.
Generation of unique 9-mers
All proteins assigned to either normal or cancer pathology states
were divided into overlapping 9-meric peptide sequences. Peptide
sequences that were found in both groups were removed, leading
to the creation of two sets of unique 9-mer peptides. There are
1,856,231 unique 9-mers in the normal group (N-peptidome) and
1,684,028 unique 9-mers in the cancer group (C-peptidome). Note
that normal and cancer sets do not consist of complete proteins;
they only consist of unique 9-meric peptides not found in the other
set. Permutated sets of both the unique N and unique C set were
created. For each set, one locally permutated and one globally
permutated set of 9-meric peptides was generated. The local
permutated sets were constructed by permuting each 9-mer, thus
keeping the amino acid composition within each 9-mer fixed. The
global permutated sets were made by randomly constructing new
9-mers out of all amino acids within each set. This preserves the
overall amino acid composition within the unique N and C sets,
local properties within each 9-mer are, however, destroyed.
Prediction of potential HLA class I epitopes
The prediction method NetMHCpan-2.4 [29,30] was used for
predicting potential epitopes for the 12 HLA class I supertypes
[31]. The NetMHCpan-2.4 method was trained on an experi-
mentally validated data set of more than 100,000 quantitative
peptide – HLA class I interactions covering more than 100 HLA
molecules and has been evaluated as the best pan-specific method
for HLA peptide binding in a large benchmark study [32]. A
general accepted threshold for binding is a rank score of 1%
[33,34] (binding strength falling within the top 1% compared to a
large set of random natural peptides), which is also the threshold,
used throughout this study.
The percentages of potential epitopes per 9-mer for all 6 sets
(normal 9-mers, normal globally permutated 9-mers, normal
locally permutated 9-mers, cancer 9-mers, cancer globally
permutated 9-mers and cancer locally permutated 9-mers) were
calculated. P-values for difference in percentage of predicted
epitopes between normal and cancer 9-mers for non-permutated
and permutated subsets were calculated by a 2-sample test for
equality of proportions and adjusted for multiple testing
(Bonferroni correction).
Amino acid scales
The amino acid abundance for normal tissue compared to
cancer tissue was determined based on all unique 9-mers in the
two data sets. The relative frequencies for all amino acids in both
the normal and cancer sets were calculated. Observed ratio of
frequencies (N/C) of amino acids among normal and cancer
tissues was correlated with Hopp-Woods hydrophilicity [35] and
Wimley-White hydrophobicity scale [36] values. The ratio was
further correlated with a mean ranking scale per amino acid as
published by Simpso]. According to Simpson [37], the scale is
based on the mean ranking of amino acids according to the
frequency of their occurrence at each sequence rank for 38
published hydrophobicity scales [38]. Other investigated scales are
average volume of buried residues [39,40], van der Waals volume
[41] and total accessible surface area [42].
Bootstrapping was applied to test if an amino acid property
scale is correlated with enriched expression of residues in either
unique normal or cancer 9-mers. For each scale, the Spearman
rank correlation coefficient was calculated and the significance of
the correlation was estimated using exact permutation test.
Table 3. eVOC terms used for cancer subset.
Burkitts lymphoma Glioblastoma Myeloid leukemia
Ewings sarcoma Glioma Myeloma
T-cell leukemia Hypertrophic
cardiomyopathy
Neoplasia
Wilms tumor Insulinoma Neuroblastoma
Adenocarcinoma Leiomyosarcoma Oligodendroglioma
Adenoma Leukaemia Osteosarcoma
Astrocytoma Liposarcoma Papillary serous
carcinoma
Carcinoid Lymphoblastic
leukemia
Phaeochromocytoma
Carcinoma Lymphocytic Polyp
Carcinoma in situ Lymphoma Retinoblastoma
Chondrosarcoma Aalignant tumour Rhabdomyosarcoma
Choriocarcinoma Medulloblastoma Sarcoma
Enchondroma Melanoma Seminoma
Fibrosarcoma Meningioma Teratocarcinoma
Fibrothecoma Monocytic
leukemia
Tumour
doi:10.1371/journal.pone.0038670.t003
Table 4. Number of transcripts and genes per set.
Normal Cancer
Number of transcripts 30,739 27,967
Number of genes 11,980 10,730
Number of uniquely associated transcripts 16,566 13,794
Number of uniquely associated genes 8,741 7,128
Average number of unique transcripts/gene 1.90 1.94
Transcripts were extracted from the ASTD database. Number of transcripts and
genes associated with normal and cancer pathology terms are given.
doi:10.1371/journal.pone.0038670.t004
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HLA motif bias
HLA binding motifs were generated from NetMHCpan-2.4
training data. Position specific weight-matrices were calculated
using sequence weighting and correction for low counts [43].
Sequence logos were visualized as described by Schneider and
Stephens [44], where each letter represents its proportional
frequency of the corresponding amino acid at that position. Based
on amino acid frequencies and observed ratio of frequencies (N/C)
of amino acids among normal and cancer tissues, we calculated for
the HLA-A*A02:01, HLA-A*A01:01 and HLA-A*A03:01 motifs
their respective overall bias towards either our defined normal or
cancer peptide set. This was done for all 20 amino acids and for
the 5 most frequent amino acid occurrences per motif. Per
position, the tendency to fit preferably to either the normal or the
cancer peptidome was calculated by summation of the respective
amino acid frequencies multiplied with the related N/C values for
all 20 amino acids. Likewise the calculation for the 5 most frequent
amino acid occurrences per motif, where only the subset of the
motifs 5 most frequent amino acid occurrences at this position is
considered. Similar to the N/C ratio, a motifs bias to preferably fit
to our normal set is given, if the average over all position for a
motif is larger than 1.
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